Abstract
Treating patients with hemophilia and inhibitors is often problematic. The presence of inhibitors negatively impacts the effectiveness of treatment to achieve hemostasis especially in patients with hemophilia B, owing mainly to allergic reactions to factor IX (FIX) concentrates and the low success rate of immune tolerance therapy. A 9-month-old boy had intracranial hemorrhage and was diagnosed with hemophilia B. After replacement therapy, he developed inhibitors and an allergic reaction to FIX. Prophylactic therapy was initiated with recombinant activated factor VII (rFVIIa) and later switched to pdFVIIa/factor X (FX; 120 μg/kg as the FVII dose, every other day) because of a recurrence of intracranial hemorrhage. Since then, he remained well without life-threatening bleeding for more than 2 years. Our case suggests that pdFVIIa/FX may be useful for prophylactic therapy in hemophilia B complicated by inhibitors and allergic reaction to FIX concentrates.
References
1.
Chitlur
M
, Warrier
I
, Rajpurkar
M
, Lusher
JM
. Inhibitors in factor IX deficiency a report of the ISTH-SSC international FIX inhibitor registry (1997-2006)
. Haemophilia
. 2009
Sep
;15
(5
):1027
–31
.
[PubMed]
1351-82162.
Recht
M
, Pollmann
H
, Tagliaferri
A
, Musso
R
, Janco
R
, Neuman
WR
. A retrospective study to describe the incidence of moderate to severe allergic reactions to factor IX in subjects with haemophilia B
. Haemophilia
. 2011
May
;17
(3
):494
–9
.
[PubMed]
1351-82163.
Shinkoda
Y
, Shirahata
A
, Fukutake
K
, Takamatsu
J
, Shima
M
, Hanabusa
H
, et al A phase III clinical trial of a mixture agent of plasma-derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors
. Haemophilia
. 2017
Jan
;23
(1
):59
–66
.
[PubMed]
1351-82164.
Shirahata
A
, Fukutake
K
, Mimaya
J
, Takamatsu
J
, Shima
M
, Hanabusa
H
, et al Results of clot waveform analysis and thrombin generation test for a plasma-derived factor VIIa and X mixture (MC710) in haemophilia patients with inhibitors—phase I trial: 2nd report
. Haemophilia
. 2013
Mar
;19
(2
):330
–7
.
[PubMed]
1351-82165.
Shirahata
A
, Fukutake
K
, Mimaya
J
, Takamatsu
J
, Shima
M
, Hanabusa
H
, et al Clinical pharmacological study of a plasma-derived factor VIIa and factor X mixture (MC710) in haemophilia patients with inhibitors—phase I trial
. Haemophilia
. 2012
Jan
;18
(1
):94
–101
.
[PubMed]
1351-82166.
Tomokiyo
K
, Nakatomi
Y
, Araki
T
, Teshima
K
, Nakano
H
, Nakagaki
T
, et al A novel therapeutic approach combining human plasma-derived Factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with Factor VIIa alone
. Vox Sang
. 2003
Nov
;85
(4
):290
–9
.
[PubMed]
0042-90077.
Nakatomi
Y
, Nakashima
T
, Gokudan
S
, Miyazaki
H
, Tsuji
M
, Hanada-Dateki
T
, et al Combining FVIIa and FX into a mixture which imparts a unique thrombin generation potential to hemophilic plasma: an in vitro assessment of FVIIa/FX mixture as an alternative bypassing agent
. Thromb Res
. 2010
May
;125
(5
):457
–63
.
[PubMed]
0049-38488.
Suzuki
T
, Chikasawa
Y
, Hagiwara
T
, Bingo
M
, Yamamoto
Y
, Amano
K
, et al Long term hemostatic efficacy of once a week administaration with a combination medicine of plasma derived factor VIIa and factor X for a hemophilia B patient with inhibitor.
https://www.postersessiononline.eu/173580348_eu/congresos/ISTH2017/aula/-PB_980_ISTH2017.pdf9.
Dioun
AF
, Ewenstein
BM
, Geha
RS
, Schneider
LC
. IgE-mediated allergy and desensitization to factor IX in hemophilia B
. J Allergy Clin Immunol
. 1998
Jul
;102
(1
):113
–7
.
[PubMed]
0091-674910.
Gamerman
S
, Singh
AM
, Makhija
M
, Sharathkumar
A
. Successful eradication of inhibitor in a patient with severe haemophilia B and anaphylaxis to factor IX concentrates: is there a role for Rituximab and desensitization therapy?
Haemophilia
. 2013
Nov
;19
(6
):e382
–5
.
[PubMed]
1351-821611.
Mahlangu
JN
. Updates in clinical trial data of extended half-life recombinant factor IX products for the treatment of haemophilia B
. Ther Adv Hematol
. 2018
Oct
;9
(11
):335
–46
.
[PubMed]
2040-620712.
Nathwani
AC
, Reiss
UM
, Tuddenham
EG
, Rosales
C
, Chowdary
P
, McIntosh
J
, et al Long-term safety and efficacy of factor IX gene therapy in hemophilia B
. N Engl J Med
. 2014
Nov
;371
(21
):1994
–2004
.
[PubMed]
0028-479313.
Miesbach
W
, Meijer
K
, Coppens
M
, Kampmann
P
, Klamroth
R
, Schutgens
R
, et al Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B
. Blood
. 2018
Mar
;131
(9
):1022
–31
.
[PubMed]
0006-497114.
Shapiro
AD
, Angchaisuksiri
P
, Astermark
J
, Benson
G
, Castaman
G
, Chowdary
P
, et al Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial results
. Blood
. 2019
Nov
;134
(22
):1973
–82
.
[PubMed]
0006-497115.
Eichler
H
, Angchaisuksiri
P
, Kavakli
K
, Knoebl
P
, Windyga
J
, Jiménez-Yuste
V
, et al Concizumab restores thrombin generation potential in patients with haemophilia: Pharmacokinetic/pharmacodynamic modelling results of concizumab phase 1/1b data
. Haemophilia
. 2019
Jan
;25
(1
):60
–6
.
[PubMed]
1351-821616.
Pasi
KJ
, Rangarajan
S
, Georgiev
P
, Mant
T
, Creagh
MD
, Lissitchkov
T
, et al Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy
. N Engl J Med
. 2017
Aug
;377
(9
):819
–28
.
[PubMed]
0028-4793© 2020 S. Karger AG, Basel
2020
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
